3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
442
Stomach Neoplasms
290
Rectal Neoplasms
266
Colonic Neoplasms
191
Pancreatic Neoplasms
175
Neoplasm Metastasis
110
Esophageal Neoplasms
87
Neoplasms
68
Carcinoma, Hepatocellular
59
Adenocarcinoma Of Esophagus
47
Adenocarcinoma
46
Lymphoma, Large B-Cell, Diffuse
44
Cholangiocarcinoma
44
Carcinoma, Non-Small-Cell Lung
41
Biliary Tract Neoplasms
37
Gallbladder Neoplasms
30
Gastrointestinal Neoplasms
29
Recurrence
25
Liver Neoplasms
24
Ovarian Neoplasms
23
Esophageal Squamous Cell Carcinoma
23
Breast Neoplasms
22
Peritoneal Neoplasms
17
Bile Duct Neoplasms
17
Unspecified Adult Solid Tumor, Protocol Specific
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Locally Advanced Rectal Cancer
13
Head and Neck Neoplasms
13
Lung Neoplasms
12
Lymphoma, Non-Hodgkin
11
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
nilotinib
1
neratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Disease Progression
×
Oxaliplatin
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts